Top

Published in:

01-01-2017 | Original Article

Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry

Authors: Francyne Kubaski, Robert W. Mason, Akiko Nakatomi, Haruo Shintaku, Li Xie, Naomi N. van Vlies, Heather Church, Roberto Giugliani, Hironori Kobayashi, Seiji Yamaguchi, Yasuyuki Suzuki, Tadao Orii, Toshiyuki Fukao, Adriana M. Montaño, Shunji Tomatsu

Published in: Journal of Inherited Metabolic Disease | Issue 1/2017

Abstract

Background

Mucopolysaccharidoses (MPS) are a group of inborn errors of metabolism that are progressive and usually result in irreversible skeletal, visceral, and/or brain damage, highlighting a need for early diagnosis.

Methods

This pilot study analyzed 2862 dried blood spots (DBS) from newborns and 14 DBS from newborn patients with MPS (MPS I, n = 7; MPS II, n = 2; MPS III, n = 5). Disaccharides were produced from polymer GAGs by digestion with chondroitinase B, heparitinase, and keratanase II. Heparan sulfate (0S, NS), dermatan sulfate (DS) and mono- and di-sulfated KS were measured by liquid chromatography tandem mass spectrometry (LC-MS/MS). Median absolute deviation (MAD) was used to determine cutoffs to distinguish patients from controls. Cutoffs were defined as median + 7× MAD from general newborns.

Results

The cutoffs were as follows: HS-0S > 90 ng/mL; HS-NS > 23 ng/mL, DS > 88 ng/mL; mono-sulfated KS > 445 ng/mL; di-sulfated KS > 89 ng/mL and ratio di-KS in total KS > 32 %. All MPS I and II samples were above the cutoffs for HS-0S, HS-NS, and DS, and all MPS III samples were above cutoffs for HS-0S and HS-NS. The rate of false positives for MPS I and II was 0.03 % based on a combination of HS-0S, HS-NS, and DS, and for MPS III was 0.9 % based upon a combination of HS-0S and HS-NS.

Conclusions

Combination of levels of two or more different GAGs improves separation of MPS patients from unaffected controls, indicating that GAG measurements are potentially valuable biomarkers for newborn screening for MPS.

Available only for authorised users

Auclair D, Hopwood JJ, Brooks DA et al (2003) Replacement therapy in Mucopolysaccharidosis type VI: advantages of early onset of therapy. Mol Genet Metab 78:163–174CrossRefPubMed

Baldo G, Matte U, Artigalas O et al (2011) Placenta analysis of prenatally diagnosed patients reveals early GAG storage in mucopolysaccharidoses II and VI. Mol Genet Metab 103:197–198CrossRefPubMed

Baldo G, Mayer FQ, Martinelli BZ et al (2013) Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice. Mol Genet Metab 109:33–40CrossRefPubMed

Beck M, Braun S, Coerdt W et al (1992) Fetal presentation of Morquio disease type A. Prenat Diagn 12:1019–1029CrossRefPubMed

Blanchard S, Sadilek M, Scott CR et al (2008) Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis I. Clin Chem 54:2067–2070CrossRefPubMedPubMedCentral

Chace DH, Hannon WH (2010) Impact of second-tier testing on the effectiveness of newborn screening. Clin Chem 56:1653–1655CrossRefPubMed

de Ruijter J, Minke HR, Wagemans T et al (2012) Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses type I, II and III. Mol Genet Metab 107:705–710CrossRefPubMed

Gabrielli O, Clarke LA, Bruni S et al (2010) Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics 125:183–187CrossRef

Gelb MH, Turecek F, Scott CR et al (2006) Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis 29:397–404CrossRefPubMedPubMedCentral

Gelb MH, Scott CR, Turecek F (2015) Newborn screening for lysosomal storage diseases. Clin Chem 61:335–346CrossRefPubMed

Gucciardi A, Legini E, Di Gangi IM et al (2014) A column-switching HPLC-MS/MS method for mucopolysaccharidosis type I analysis in a multiplex assay for the simultaneous newborn screening of six lysosomal storage disorders. Biomed Chromatogr 28:1131–1139CrossRefPubMed

Hennessey PT, Hurst RE, Hemstreet GP et al (1981) Urinary glycosaminoglycan excretion as a biochemical marker in patients with bladder carcinoma. Cancer Res 41:3868–3873PubMed

Hopkins PV, Campbell C, Klug T et al (2015) Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. J Pediatr 166:172–177CrossRefPubMed

Komosinska-Vassev K, Olczyk K, Kozma EM et al (2005) Alterations of glycosaminoglycan metabolism in the development of diabetic complications in relation to metabolic control. Clin Chem Lab Med 43:924–929CrossRefPubMed

Lawrence R, Brown JR, Al-Mafraji K et al (2012) Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses. Nat Chem Biol 8:197–204CrossRefPubMedPubMedCentral

Lawrence R, Brown JR, Lorey F et al (2014) Glycan-based biomarkers for mucopolysaccharidoses. Mol Genet Metab 111:73–83CrossRefPubMed

Leys C, Ley C, Klein O et al (2013) Detecting outliers: do not use standard deviation around the mean, use absolute deviation around the median. J Exp Soc Psychol 49:764–766CrossRef

Liao HC, Chiang CC, Niu DM et al (2014) Detecting multiple lysosomal storage diseases by tandem mass spectrometry—a national newborn screening program in Taiwan. Clin Chem Acta 431:80–86CrossRef

Lin SP, Lin HY, Wang TJ et al (2013) A pilot newborn screening program for Mucopolysaccharidosis type I in Taiwan. Orphanet J Rare Dis 22:1–8

Mankin HJ, Lippiello L et al (1971) The glycosaminoglycans of normal and arthritic cartilage. J Clin Invest 50:1712–1719CrossRefPubMedPubMedCentral

Martin JJ, Ceuterick C (1983) Prenatal pathology in mucopolysaccharidoses: a comparison with postnatal cases. Clin Neuropathol 2:122–127PubMed

McGill JJ, Inwood AC, Coman DJ et al (2010) Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age—a sibling control study. Clin Genet 77:492–498CrossRefPubMed

Meikle PJ, Grasby DJ, Dean CJ et al (2006) Newborn screening for lysosomal storage disorders. Mol Genet Metab 88:307–314CrossRefPubMed

Muenzer J (2014) Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol Genet Metab 111:63–72CrossRefPubMed

Neufeld E, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3421–3452

Oguma T, Tomatsu S, Montaño AM et al (2007) Analytical method for determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography/turbo ionspray ionization tandem mass spectrometry. Anal Biochem 368:79–86CrossRefPubMed

Ohashi A, Montaño AM, Colón JE et al (2009) Sacral dimple: incidental findings from newborn evaluation. Mucopolysaccharidosis IVA disease. Acta Paediatr 98:768–769CrossRefPubMed

Poe MD, Chagnon SL, Escolar ML (2014) Early treatment is associated with improved cognition in Hurler syndrome. Ann Neurol 76:1–24CrossRef

R Core Team (2014) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. (http://www.R-project.org/)

Rowan DJ, Tomatsu S, Grubb JH et al (2013) Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIA, IVA and VII. J Inherit Metab Dis 36:235–246CrossRefPubMed

Ruijter GJ, Goudriaan DA, Boer AM et al (2014) Newborn screening for hunter disease: a small-scale feasibility study. J Inherit Metab Dis Rep 14:23–27

Saad OM, Ebel H, Uchimura K et al (2005) Compositional profiling of heparin/heparan sulfate using mass spectrometry: assay for specificity of a novel extracellular human endosulfatase. Glycobiology 15:818–826CrossRefPubMed

Schulze-Frenking G, Jones SA, Roberts J et al (2011) Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. J Inherit Metab Dis 34:203–208CrossRefPubMed

Scott CR, Elliott S, Buroker N et al (2013) Identification of infants at risk for developing Fabry, Pompe, or Mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. J Pediatr 163:498–503CrossRefPubMedPubMedCentral

Shimada T, Kelly J, LaMarr WA et al (2014a) Novel heparan sulfate assay by using automated high-throughput mass spectrometry: application to monitoring and screening for mucopolysaccharidoses. Mol Genet Metab 113:92–99CrossRefPubMedPubMedCentral

Shimada T, Tomatsu S, Yasuda E et al (2014b) Chondroitin 6-sulfate as a novel biomarker for mucopolysaccharidosis type I, IIIA, IVA and VII. J Inherit Metab Dis Rep 16:15–24

Shimada T, Tomatsu S, Mason RW et al (2015) Di-sulfated KS as a novel biomarker for mucopolysaccharidosis II, IVA, and IVB. J Inherit Metab Dis Rep 21:1–13

Spacil Z, Tatipaka H, Barcenas M et al (2013) High-throughput assay of 9 lysosomal enzymes for newborn screening. Clin Chem 59:502–511CrossRefPubMedPubMedCentral

Tomatsu S, Orii KO, Vogler C et al (2003) Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns−/−) produced by targeted disruption of the gene defective in Morquio A Disease. Hum Mol Genet 12:3349–3358CrossRefPubMed

Tomatsu S, Okamura K, Maeda H et al (2005) Keratan sulphate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis 28:187–202CrossRefPubMed

Tomatsu S, Montaño AM, Oguma T et al (2010) Validation of keratan sulfate level in mucopolysaccharidosis IVA by liquid tandem mass spectrometry method. J Inherit Metab Dis 33:35–42CrossRef

Tomatsu S, Fujii T, Fukushi M et al (2013) Newborn screening and diagnosis of mucopolysaccharidoses. Mol Genet Metab 110:42–53CrossRefPubMedPubMedCentral

Tomatsu S, Shimada T, Mason RW et al (2014) Establishment of glycosaminoglycan assays for mucopolysaccharidoses. Metabolites 4:655–679CrossRefPubMedPubMedCentral

Tomatsu S, Almeciga-Diaz CJ, Montano AM et al (2015) Therapies for the bone in mucopolysaccharidoses. Mol Genet Metab 114:94–109CrossRefPubMed

Tomatsu S, Azario I, Sawamoto K et al (2016) Neonatal cellular and gene therapies for mucopolysaccharidoses: the earlier the better? J Inherit Metab Dis 39:189–202CrossRefPubMed

Turgeon CT, Magera MJ, Cuthbert CD et al (2010) Determination of total homocysteine, methylmalonic acid, and 2-methylcitric acid in dried blood spots by tandem mass spectrometry. Clin Chem 56:1686–1695CrossRefPubMed

U.S. Department of Health and Human Services (2001) Guidance for Industry. Bioanalytical method validation. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Veterinary Medicine (CVM). Available at: http://www.fda.gov/downloads/Drugs/…/Guidances/ucm070107.pdf

Vogler C, Birkenmeier EH, Sly WS et al (1990) A murine model of mucopolysaccharidosis VII. Gross and microscopic findings in beta-glucuronidase-deficient mice. Am J Pathol 136:207–217PubMedPubMedCentral

Wei W, Ninñonuevo MR, Sharma A et al (2011) A comprehensive compositional analysis of heparin/heparan sulfate-derived disaccharides from human serum. Anal Chem 83:3703–3708CrossRefPubMedPubMedCentral

Wolfe BJ, Blanchard S, Sadilek M et al (2011) Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis II (Hunter syndrome). Anal Chem 83:1152–1156CrossRefPubMed

Zhang Y, Conrad AH, Tasheva ES et al (2005) Detection and quantification of sulfated disaccharides from keratin sulfate and chondroitin/dermatan sulfate during chick corneal development by ESI-MS/MS. Invest Ophthalmol Vis Sci 46:1604–1614CrossRefPubMed

Title: Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry
Authors: Francyne Kubaski
Robert W. Mason
Akiko Nakatomi
Haruo Shintaku
Li Xie
Naomi N. van Vlies
Heather Church
Roberto Giugliani
Hironori Kobayashi
Seiji Yamaguchi
Yasuyuki Suzuki
Tadao Orii
Toshiyuki Fukao
Adriana M. Montaño
Shunji Tomatsu
Publication date: 01-01-2017
Publisher: Springer Netherlands
Published in: Journal of Inherited Metabolic Disease / Issue 1/2017
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-016-9981-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Jean-Marie Saudubray, Matthias R. Baumgartner, John Walter (Eds.). Inborn metabolic diseases: diagnosis and treatment

Pathogenic variants in HTRA2 cause an early-onset mitochondrial syndrome associated with 3-methylglutaconic aciduria

Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision

Assessment of ataxia phenotype in a new mouse model of galactose-1 phosphate uridylyltransferase (GALT) deficiency

Lethal neonatal hyperammonemia in severe ornithine transcarbamylase (OTC) deficiency compounded by large hepatic portosystemic shunt

Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials